Sign in
Taking people in United StatesPhase 4

Comparing common sleep medicines for adults with long-term insomnia

Compares prescription and store-bought sleep medicines in adults with insomnia.

Key facts

Who runs it
University of Pennsylvania
Where
Philadelphia, United StatesSee the site
Trial code
Registry title
A SMART Approach to Evaluating the Benefits of Common Prescription and OTC Medications for Insomnia
Status
Recruiting
Phase
Phase 4
People taking part
1,200 people, planned
Started
1 May 2026
Expected to end
1 Jan 2032
Type of study
Interventional, 6 groupsOne group gets a placebo (a dummy treatment), for comparison.
Treatments tested
  • Sleep Hygiene Education
  • Melatonin IR, 3 mg
  • Melatonin IR, 5 mg
  • Diphenhydramine, 25 mg
  • Diphenhydramine, 50 mg
  • Doxepin, 3 mg
  • Doxepin, 6 mg
  • Trazodone, 50 mg
  • Trazodone, 100 mg
  • Placebo
  • Zolpidem, 5 mg
  • Zolpidem, 10 mg
Record updated
16 September 2026

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults with long-term insomnia. It compares common prescription and over-the-counter sleep medicines with a placebo.

Age
18 to 80 years
Sex
All sexes
Disease stage
Insomnia Disorder by DSM-5 criteria, with a score of 15 or more on the Insomnia Severity Index (ISI). Trouble falling or staying asleep for 30 minutes or more, on 3 or more nights a week, for 3 months or more.
Earlier treatment
People must stop all sleep-related medicines before joining and complete a 2-week washout period. They must stop CNS active drugs not allowed by the protocol, and moderate or strong CYP3A4 inhibitors.

Main reasons for not taking part

  • Pregnant, breastfeeding or planning a pregnancy
  • Breathing disorders such as COPD or sleep apnea, other sleep disorders, night or rotating shift work, or napping 1 hour or more a day on 3 or more days a week
  • Past suicide attempts or current suicidal thoughts, or unstable mental or physical illness
  • Alcohol or substance use disorder in the 2 years before screening, or heavy smoking
  • Significant liver or kidney problems, epilepsy, glaucoma, urinary retention, pheochromocytoma or porphyria

The registry criteria, word for word

Show all 31 criteriaShow less

Who can take part

  • Adults aged 18-80 years
  • Meet DSM-5 criteria for Insomnia Disorder
  • Score ≥15 on the Insomnia Severity Index (ISI)
  • Sleep initiation and/or maintenance complaints: ≥30 minutes in duration, occurring ≥3 nights/week, with a duration of ≥3 months
  • Willingness to discontinue use of all sleep-related medications prior to enrollment
  • Completion of a 2-week washout period before starting any study medication
  • Willingness to provide clinician assent for participation

Who cannot take part

  • Unstable medical condition, significant medical disorder, or acute illness (as determined by their PCP), within one month prior to the study period
  • Diagnosis of alcohol or substance use disorder within 2 years prior to the screening visit
  • Self-reported usual daytime napping ≥1 hour per day (3 or more days per week); Medications and Concomitant meds
  • Treatment with CNS active drugs prohibited by the protocol for five half-lives of the respective drug (or 2 weeks); Lifestyle
  • Not able or willing to stop treatment with moderate or strong cytochrome P450 3A4 (CYP3A4) inhibitors
  • Patients will be ineligible if they meet any of the following criteria: self-reported daytime napping (≥1 hour per day on ≥3 days per week); a history of suicidal attempts or current ideation, acute or chronic psychiatric or medical condition not controlled by therapy (according to their primary care physician), or current alcohol or drug misuse; or the diagnoses of (or high risk for) other sleep disorders, including circadian rhythm disorders (phase advance or phase delay syndromes), shift work related sleep disorder ("day sleepers" who work ~11pm to 7am) and those with rotating shiftwork schedules. To determine eligibility, all subjects will be screened using a multitier process including: an online screener; an intake interview; a review of the subjects EMR; and, finally, the receipt of the patient's PCP's assent. The following provides additional listing and details (AD) for the Exclusion Criteria:
  • Acute or unstable psychiatric conditions
  • Epilepsy or Seizure Disorder (contraindicated for trazodone)
  • Inability to refrain from drinking alcohol or substance use for at least 3 consecutive days; Sleep Disorders and Sleep Habits
  • Any lifetime history of (diagnosis of) breathing disorders, including COPD and sleep apnea
  • Shift work related sleep disorder (work ~11pm to 7am and "day sleeper") and rotating shiftwork schedules
  • Circadian rhythm disorders (phase advance or phase delay syndromes)
  • Known hypersensitivity or contraindication to study drugs
  • Known hypersensitivity or contraindication to drugs of the same class as the study treatments
  • Known hypersensitivity or contraindication to any excipients of the study drug formulation
  • Age < 18 or > 80 years old
  • Minimal facility with smartphones, computers, i-Pads, or the internet; Women's Health Given the potential for teratogenic effects with at least trazodone (FDA Class C), women intending to become pregnant, or who are pregnant, or who are breastfeeding will not be eligible for the study. Women will be asked to confirm the use of birth control using self-report and, if applicable, by providing evidence of contraceptive medication (e.g., prescription or pill pack). We will perform a urine pregnancy test at baseline for female participants who are of reproductive age to confirm eligibility. At study enrollment, participants will be told to alert the study team and stop taking study medications if they become pregnant. Participants will be asked to test for pregnancy in the event of a missed cycle; Medical and Psychiatric Considerations
  • General Considerations
  • Inadequate English language comprehension
  • Significant liver or kidney problems
  • Pheochromocytoma or porphyria (contraindicated for trazodone)
  • Glaucoma or urinary retention (contraindicated for doxepin)
  • Increased ocular pressure (contraindicated for diphenhydramine)
  • Heavy tobacco use (≥1 pack of cigarettes a day or inability to refrain from smoking during the night)

Check if you might fit

Answer for yourself. This is not a decision: only the study team can say whether you can take part.

  • Are you between 18 and 80 years old?

Where in United States

  • University of PennsylvaniaPhiladelphia, United StatesContact: Michael L Perlis, PhDTaking people

About the trial

What the trial wants to find out

The purpose of this study is to assess the relative effectiveness, safety, and durability of the most commonly used prescription (zolpidem, trazodone) and over-the-counter (OTC) (melatonin, diphenhydramine) medications for insomnia, as well as a less commonly used prescription that may have a better risk/benefit profile (doxepin).

The 6 groups in the trial

  • MelatoninTreatment being tested

    Nightly 30 minutes prior to bed (3 or 5 mg)

    Treatment: Sleep Hygiene Education, Melatonin IR, 3 mg, and Melatonin IR, 5 mg

  • PlaceboPlacebo, for comparison

    Nightly 30 minutes prior to bed

    Treatment: Sleep Hygiene Education and Placebo

  • DiphenhydramineTreatment being tested

    Nightly 30 minutes prior to bed (25 or 50 mg). Note: Given the strong recommendation against the use of diphenhydramine in older adults (i.e., the Beers Criteria), participants ≥64 years of age will not be randomized to the diphenhydramine arm.

    Treatment: Sleep Hygiene Education, Diphenhydramine, 25 mg, and Diphenhydramine, 50 mg

  • ZolpidemTreatment being tested

    Nightly 30 minutes prior to bed (5 or 10 mg)

    Treatment: Sleep Hygiene Education, Zolpidem, 5 mg, and Zolpidem, 10 mg

  • DoxepinTreatment being tested

    Nightly 30 minutes prior to bed (3 or 6 mg)

    Treatment: Sleep Hygiene Education, Doxepin, 3 mg, and Doxepin, 6 mg

  • TrazodoneTreatment being tested

    Nightly 30 minutes prior to bed (50 or 100 mg)

    Treatment: Sleep Hygiene Education, Trazodone, 50 mg, and Trazodone, 100 mg

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Saves a reminder to your own calendar to look at this page again. Frontlight sends no messages and does not know you set it.

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Sequential Multiple Assignment Randomized Trial Comparing Commonly Prescribed and Over the Counter Medications for the Treatment of Insomnia in Adults
Plain-language title
Comparing common sleep medicines for adults with long-term insomniaGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 14 November 2026.
Fit questions
Built from NCT07542756, who can take part
Record updated
16 September 2026